Equity Profile

ACAD

ACADIA Pharmaceuticals Inc.

Health CareBiotechnology$4.4B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

ACADIA Pharmaceuticals Inc. is a biotechnology company focused on developing innovative therapies for central nervous system disorders....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will show how well ACADIA is managing its costs and revenues.

N/A

Revenue Growth

Revenue growth will indicate the demand for ACAD's products and its market position within the biotechnology industry.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ACAD Q2-2026 Earnings Preview

Context

Company Snapshot

ACADIA Pharmaceuticals Inc. is a biotechnology company focused on developing innovative therapies for central nervous system disorders. With a market cap of $4 billion, its work is significant in the health care sector, particularly as mental health issues gain more attention and funding.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+226.66%

Avg Stock Reaction

+1.25%

Last Quarter Recap

In Q1-2026, ACADIA reported an EPS of $0.02, which was below the expected $0.04, resulting in a 3.89% drop in stock price the following day. This miss raised concerns about the company's growth trajectory.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as ACADIA has a history of beating EPS estimates, but recent performance has raised doubts. Investors will be keenly watching for any signs of recovery in earnings and revenue growth.

Bull Case

If ACADIA can demonstrate strong revenue growth and return to profitability, it could regain investor confidence and see a positive stock reaction.

Bear Case

Conversely, if the company continues to miss earnings expectations and fails to provide a clear path to growth, it may face further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the recent miss in Q1-2026, investors will closely scrutinize whether ACADIA can return to profitability.

What is the revenue growth outlook for the next quarter?

Revenue growth is crucial for assessing the company's market position and future potential, especially after recent performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating ACADIA's potential for a rebound given its strong history of EPS beats, despite recent setbacks.

Supporting Evidence

ACADIA has an 88% EPS beat rate historically, indicating potential for recovery.

Options pricing suggests a larger move than historically realized, indicating investor uncertainty.

The company has a strong pipeline that could drive future growth, which may not be fully reflected in current stock prices.

Key Risk

If ACADIA reports an EPS above $0.04, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter centers around whether ACADIA can turn around its earnings performance and demonstrate sustainable growth.

Bull Confirmed If

A return to an EPS of at least $0.04 or higher would confirm the bull case and indicate a recovery.

Bear Confirmed If

An EPS below $0.02 would confirm the bear case and raise concerns about the company's viability.

Pre-Earnings Positioning

Options Market

Implied Move

±10.63%

Historical Avg

±2.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±10.6% while ACAD has averaged ±2.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

33.8%

Calls (134K)P/C Ratio: 0.05Puts (500)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ACADIA beats expectations, history suggests a stock increase of around 1.98%, confirming a recovery narrative.

In-Line / Cautious

If results are in line but cautious, the stock may see muted movement as investors await more clarity.

Miss

A miss could lead to a decline of about 3.89%, reinforcing negative sentiment around the company's growth prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements.
2Details on cost management strategies.
3Insights into market demand for current therapies.
4Guidance on revenue expectations for the next quarter.
5Management's commentary on competitive landscape changes.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

ACADIA Pharmaceuticals Inc. is a biotechnology company focused on developing innovative therapies for central nervous system disorders....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will show how well ACADIA is managing its costs and revenues.

N/A

Revenue Growth

Revenue growth will indicate the demand for ACAD's products and its market position within the biotechnology industry.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ACAD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+226.66%

Avg Stock Reaction

+1.25%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If ACADIA can demonstrate strong revenue growth and return to profitability, it could regain investor confidence and see a positive stock reaction.

Bear Case

Conversely, if the company continues to miss earnings expectations and fails to provide a clear path to growth, it may face further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the recent miss in Q1-2026, investors will closely scrutinize whether ACADIA can return to profitability.

What is the revenue growth outlook for the next quarter?

Revenue growth is crucial for assessing the company's market position and future potential, especially after recent performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating ACADIA's potential for a rebound given its strong history of EPS beats, despite recent setbacks.

Supporting Evidence

ACADIA has an 88% EPS beat rate historically, indicating potential for recovery.

Options pricing suggests a larger move than historically realized, indicating investor uncertainty.

The company has a strong pipeline that could drive future growth, which may not be fully reflected in current stock prices.

Key Risk

If ACADIA reports an EPS above $0.04, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter centers around whether ACADIA can turn around its earnings performance and demonstrate sustainable growth.

Bull Confirmed If

A return to an EPS of at least $0.04 or higher would confirm the bull case and indicate a recovery.

Bear Confirmed If

An EPS below $0.02 would confirm the bear case and raise concerns about the company's viability.

Pre-Earnings Positioning

Options Market

Implied Move

±10.63%

Historical Avg

±2.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±10.6% while ACAD has averaged ±2.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

33.8%

Calls (134K)P/C Ratio: 0.05Puts (500)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ACADIA beats expectations, history suggests a stock increase of around 1.98%, confirming a recovery narrative.

In-Line / Cautious

If results are in line but cautious, the stock may see muted movement as investors await more clarity.

Miss

A miss could lead to a decline of about 3.89%, reinforcing negative sentiment around the company's growth prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements.
2Details on cost management strategies.
3Insights into market demand for current therapies.
4Guidance on revenue expectations for the next quarter.
5Management's commentary on competitive landscape changes.